United States
Germany
Japan
United Kingdom
China
AAV2 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV Control Particles
AAV9-CMV-GFP Control Particle, 1 x 100 uL
AAV2 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 1 x 100 uL
AAV8-CMV-GFP Control Particle, 1 x 100 uL
AAV-PHP.eB-CMV-GFP Control Particle, 1 x 100 uL
AAV5 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 1 x 100 uL
AAV8 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV-PHP.eB with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV9 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV1 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAVDJ with CMV promoter-driven expression of GFP, >10^13 GC/mL, 1 x 100 uL
AAV1 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 1 x 100 uL
AAVrh.10-CMV-GFP Control Particle, 1 x 100 uL
AAV2 control particles, shRNA scramble, expressing GFP and puro, >10^13 GC/mL, 1 x 100 uL
AAV5 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
